LifeSci Capital Starts Inhibrx Biosciences (INBX) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts INBX Hot Sheet
Price: $71.78 --0%
Rating Summary:
6 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 16 | New: 15
Rating Summary:
6 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 16 | New: 15
Join SI Premium – FREE
LifeSci Capital initiates coverage on Inhibrx Biosciences (NASDAQ: INBX) with a Outperform rating and a price target of $200.00.
For an analyst ratings summary and ratings history on Inhibrx Biosciences click here. For more ratings news on Inhibrx Biosciences click here.
Shares of Inhibrx Biosciences closed at $119.93 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stephens Upgrades Oracle (ORCL) to Overweight Post Investor Day
- Northland Upgrades Coherent (COHR) to Outperform
- Rare Earths Americas reports improved leach recovery at Brazil project
Create E-mail Alert Related Categories
New CoverageRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
